NO20083031L - Tiadiazolderivater som anti-diabetiske agenter - Google Patents
Tiadiazolderivater som anti-diabetiske agenterInfo
- Publication number
- NO20083031L NO20083031L NO20083031A NO20083031A NO20083031L NO 20083031 L NO20083031 L NO 20083031L NO 20083031 A NO20083031 A NO 20083031A NO 20083031 A NO20083031 A NO 20083031A NO 20083031 L NO20083031 L NO 20083031L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- inhibitors
- prevention
- formula
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74857305P | 2005-12-08 | 2005-12-08 | |
PCT/US2006/046545 WO2007067615A2 (en) | 2005-12-08 | 2006-12-06 | Thiadiazole derivatives as antidiabetic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083031L true NO20083031L (no) | 2008-08-28 |
Family
ID=37950917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083031A NO20083031L (no) | 2005-12-08 | 2008-07-04 | Tiadiazolderivater som anti-diabetiske agenter |
Country Status (26)
Country | Link |
---|---|
US (1) | US7700633B2 (ja) |
EP (1) | EP1963292B1 (ja) |
JP (1) | JP2009519248A (ja) |
KR (1) | KR20080074969A (ja) |
CN (1) | CN101326173A (ja) |
AR (1) | AR056838A1 (ja) |
AT (1) | ATE546440T1 (ja) |
AU (1) | AU2006321905B2 (ja) |
BR (1) | BRPI0619600A2 (ja) |
CA (1) | CA2629857A1 (ja) |
CR (1) | CR10049A (ja) |
EC (1) | ECSP088506A (ja) |
ES (1) | ES2381280T3 (ja) |
IL (1) | IL191549A0 (ja) |
MA (1) | MA30202B1 (ja) |
NO (1) | NO20083031L (ja) |
NZ (1) | NZ568243A (ja) |
PE (2) | PE20071031A1 (ja) |
PL (1) | PL1963292T3 (ja) |
PT (1) | PT1963292E (ja) |
RU (1) | RU2008127254A (ja) |
TN (1) | TNSN08249A1 (ja) |
TW (1) | TW200732315A (ja) |
UA (1) | UA94724C2 (ja) |
WO (1) | WO2007067615A2 (ja) |
ZA (1) | ZA200804074B (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007067613A1 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase) |
CN101321743A (zh) * | 2005-12-08 | 2008-12-10 | 诺瓦提斯公司 | 作为ptp-酶抑制剂的1,1,3-三氧代-1,2,5-噻二唑烷和它们的用途 |
UA94921C2 (en) | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
WO2008067527A1 (en) * | 2006-12-01 | 2008-06-05 | Novartis Ag | Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders |
AR066820A1 (es) * | 2007-06-04 | 2009-09-16 | Novartis Ag | Compuestos de tiadiazolidin-3 ona |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
AU2011313191A1 (en) | 2010-10-08 | 2013-05-02 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
CA2834465A1 (en) | 2011-04-28 | 2012-11-01 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
WO2020127924A1 (en) * | 2018-12-21 | 2020-06-25 | Bionice, S.L.U. | Process and intermediates for the preparation of voxelotor |
CA3131894A1 (en) * | 2019-03-14 | 2020-09-17 | Calico Life Sciences Llc | Protein tyrosine phosphatase inhibitors and methods of use thereof |
GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
EP4077319A1 (en) * | 2019-12-20 | 2022-10-26 | Calico Life Sciences LLC | Protein tyrosine phosphatase degraders and methods of use thereof |
JP2024509962A (ja) * | 2021-03-11 | 2024-03-05 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環及びその使用 |
CA3236854A1 (en) * | 2021-11-11 | 2023-05-19 | Andrew Bogdan | Protein tyrosine phosphatase inhibitors and methods of use thereof |
WO2023150535A1 (en) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitors and uses thereof |
TW202342437A (zh) * | 2022-02-02 | 2023-11-01 | 美商耐瑞歐醫療公司 | 蛋白酪胺酸磷酸酶抑制劑及其用途 |
WO2023150150A1 (en) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitors and uses thereof |
WO2024059041A1 (en) * | 2022-09-13 | 2024-03-21 | Kumquat Biosciences, Inc. | Benzo-fused n-heterocycles and uses thereof |
WO2024067802A1 (zh) * | 2022-09-30 | 2024-04-04 | 深圳众格生物科技有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途 |
CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL372848A1 (en) | 2002-04-03 | 2005-08-08 | Novartis Ag | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors |
GB0225986D0 (en) * | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
GB0227813D0 (en) * | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
WO2004062664A1 (en) * | 2002-12-30 | 2004-07-29 | Vertex Pharmaceuticals Incorporated | Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
US7141596B2 (en) * | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
WO2007067613A1 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase) |
CN101321743A (zh) * | 2005-12-08 | 2008-12-10 | 诺瓦提斯公司 | 作为ptp-酶抑制剂的1,1,3-三氧代-1,2,5-噻二唑烷和它们的用途 |
US8084448B2 (en) * | 2006-03-31 | 2011-12-27 | Novartis Ag | Organic compounds |
-
2006
- 2006-06-12 UA UAA200807751A patent/UA94724C2/ru unknown
- 2006-12-06 ES ES06839094T patent/ES2381280T3/es active Active
- 2006-12-06 US US12/096,439 patent/US7700633B2/en not_active Expired - Fee Related
- 2006-12-06 EP EP06839094A patent/EP1963292B1/en active Active
- 2006-12-06 CA CA002629857A patent/CA2629857A1/en not_active Abandoned
- 2006-12-06 JP JP2008544467A patent/JP2009519248A/ja active Pending
- 2006-12-06 KR KR1020087013716A patent/KR20080074969A/ko not_active Application Discontinuation
- 2006-12-06 PT PT06839094T patent/PT1963292E/pt unknown
- 2006-12-06 AU AU2006321905A patent/AU2006321905B2/en not_active Ceased
- 2006-12-06 NZ NZ568243A patent/NZ568243A/en not_active IP Right Cessation
- 2006-12-06 AR ARP060105392A patent/AR056838A1/es not_active Application Discontinuation
- 2006-12-06 BR BRPI0619600-4A patent/BRPI0619600A2/pt not_active IP Right Cessation
- 2006-12-06 RU RU2008127254/04A patent/RU2008127254A/ru not_active Application Discontinuation
- 2006-12-06 PE PE2006001571A patent/PE20071031A1/es not_active Application Discontinuation
- 2006-12-06 PL PL06839094T patent/PL1963292T3/pl unknown
- 2006-12-06 AT AT06839094T patent/ATE546440T1/de active
- 2006-12-06 CN CNA2006800461637A patent/CN101326173A/zh active Pending
- 2006-12-06 PE PE2010000531A patent/PE20100733A1/es not_active Application Discontinuation
- 2006-12-06 WO PCT/US2006/046545 patent/WO2007067615A2/en active Application Filing
- 2006-12-07 TW TW095145713A patent/TW200732315A/zh unknown
-
2008
- 2008-05-13 ZA ZA200804074A patent/ZA200804074B/xx unknown
- 2008-05-19 IL IL191549A patent/IL191549A0/en unknown
- 2008-06-02 MA MA30987A patent/MA30202B1/fr unknown
- 2008-06-05 CR CR10049A patent/CR10049A/es not_active Application Discontinuation
- 2008-06-06 TN TNP2008000249A patent/TNSN08249A1/en unknown
- 2008-06-06 EC EC2008008506A patent/ECSP088506A/es unknown
- 2008-07-04 NO NO20083031A patent/NO20083031L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ568243A (en) | 2011-07-29 |
PL1963292T3 (pl) | 2012-07-31 |
TW200732315A (en) | 2007-09-01 |
WO2007067615A3 (en) | 2007-11-15 |
UA94724C2 (en) | 2011-06-10 |
CR10049A (es) | 2008-08-25 |
US7700633B2 (en) | 2010-04-20 |
TNSN08249A1 (en) | 2009-10-30 |
EP1963292A2 (en) | 2008-09-03 |
KR20080074969A (ko) | 2008-08-13 |
AR056838A1 (es) | 2007-10-24 |
PE20071031A1 (es) | 2007-11-15 |
CA2629857A1 (en) | 2007-06-14 |
AU2006321905B2 (en) | 2011-08-11 |
PT1963292E (pt) | 2012-05-10 |
JP2009519248A (ja) | 2009-05-14 |
MA30202B1 (fr) | 2009-02-02 |
ATE546440T1 (de) | 2012-03-15 |
ZA200804074B (en) | 2009-03-25 |
ES2381280T3 (es) | 2012-05-24 |
AU2006321905A1 (en) | 2007-06-14 |
RU2008127254A (ru) | 2010-01-20 |
PE20100733A1 (es) | 2010-10-29 |
BRPI0619600A2 (pt) | 2011-10-11 |
IL191549A0 (en) | 2008-12-29 |
CN101326173A (zh) | 2008-12-17 |
WO2007067615A2 (en) | 2007-06-14 |
EP1963292B1 (en) | 2012-02-22 |
ECSP088506A (es) | 2008-07-30 |
US20080262050A1 (en) | 2008-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083031L (no) | Tiadiazolderivater som anti-diabetiske agenter | |
NO20083030L (no) | 1-Orthofluorfenyl-substituert 1,2,5-tiazolidindionderivater som PTP-AS inhibitorer | |
WO2007115058A3 (en) | Thiadiazolidinone inhibitors of ptpase | |
TNSN08247A1 (en) | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors | |
NO20044745L (no) | 5-substituerte 1,1-diokso-1,2,5-tiazolidin-3-on-derivater som PTPASE 1B inhibitorer | |
Cameron et al. | Discovery and preclinical characterization of 6-chloro-5-[4-(1-hydroxycyclobutyl) phenyl]-1 H-indole-3-carboxylic acid (PF-06409577), a direct activator of adenosine monophosphate-activated protein kinase (AMPK), for the potential treatment of diabetic nephropathy | |
Liu et al. | p53 modifications: exquisite decorations of the powerful guardian | |
AR066820A1 (es) | Compuestos de tiadiazolidin-3 ona | |
WO2007136603A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
WO2007070434A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes | |
TNSN08367A1 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
NO20091700L (no) | Florizinanaloger som inhibitorer av glukose-ko-transporter 2 | |
WO2006058064A3 (en) | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
NO20070506L (no) | Fremgangsmater og mellomprodukter nyttige for fremstilling av kondenserte heterocykliske kinase inhibitorer. | |
NO20075731L (no) | Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon | |
WO2010074588A8 (en) | Pharmaceutical compounds | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
WO2007149451A3 (en) | Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors | |
NO20084396L (no) | Kombinasjonsterapi | |
EA201270215A1 (ru) | Apaf-1 ингибиторные соединения | |
MX2009010894A (es) | Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa. | |
WO2007136640A3 (en) | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | |
WO2008054698A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2006130613A3 (en) | Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |